BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 15787663)

  • 21. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
    Perriello G; Pampanelli S; Di Pietro C; Brunetti P;
    Diabet Med; 2006 Mar; 23(3):246-52. PubMed ID: 16492206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L; Koenen C; Weng W; Selam JL
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study.
    Parhofer KG; Otto C; Geiss HC; Laubach E; Göke B
    Exp Clin Endocrinol Diabetes; 2005 Jan; 113(1):49-52. PubMed ID: 15662596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
    Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
    Spanheimer R; Betteridge DJ; Tan MH; Ferrannini E; Charbonnel B;
    Am J Cardiol; 2009 Jul; 104(2):234-9. PubMed ID: 19576353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
    Kardas P
    Diabetes Obes Metab; 2005 Nov; 7(6):722-8. PubMed ID: 16219016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study.
    Hohberg C; Pfützner A; Forst T; Lübben G; Karagiannis E; Borchert M; Schöndorf T
    Diabetes Obes Metab; 2009 May; 11(5):464-71. PubMed ID: 19422402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
    Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K
    J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.
    Al-Azzam SI; Alomari M; Khader YS; Almahasneh FA; Muflih SM; Altawalbeh S
    Endocr Res; 2012; 37(1):7-11. PubMed ID: 21977974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
    Esposito K; Maiorino MI; Di Palo C; Gicchino M; Petrizzo M; Bellastella G; Saccomanno F; Giugliano D
    Diabetes Obes Metab; 2011 May; 13(5):439-45. PubMed ID: 21255215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gliclazide in the treatment of obese non-insulin dependent diabetic patients.
    Seshiah V; Venkataraman S; Suresh K
    J Assoc Physicians India; 1993 Jun; 41(6):367-8. PubMed ID: 8005974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of secondary diabetes mellitus with acromegaly improved by pioglitazone.
    Watanabe A; Komine F; Nirei K; Tamura K; Nabe K; Aiba N; Kamoshida S; Otsuka M; Okubo H; Kanou M; Sawada S; Uchiyama T; Nakamura S; Arakawa Y
    Diabet Med; 2004 Sep; 21(9):1049-50. PubMed ID: 15317614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
    Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
    Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
    Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
    Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
    Charbonnel B; Roden M; Urquhart R; Mariz S; Johns D; Mihm M; Widel M; Tan M
    Diabetologia; 2005 Mar; 48(3):553-60. PubMed ID: 15739120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.